[{"data":1,"prerenderedAt":205},["ShallowReactive",2],{"drug-deutetrabenazine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":19,"regimens":50,"contraindications":100,"warnings":110,"renal":125,"monitoring":126,"interactions":127,"review":128,"examples":131,"atc":142,"iran":144,"usApproval":151,"links":157,"populations":171},"deutetrabenazine",1,{"fa":7,"en":8},"دوتترابنازین","Deutetrabenazine","nervous-system",{"fa":11,"en":12},"مهارکننده VMAT2","VMAT2 inhibitor",[14],{"name":15,"market":16},"Austedo","US",[18,7],"austedo",[20,34,42],{"id":21,"form":22,"route":23,"label":24,"concentration":25,"markets":29,"refs":30},"tab-6","tablet","oral","6 mg tablet (swallow whole)",{"amount":26,"unit":27,"perUnit":22,"scored":28},6,"mg",false,[16],[31],{"source":32,"section":33},"fda-austedo","3",{"id":35,"form":22,"route":23,"label":36,"concentration":37,"markets":39,"refs":40},"tab-9","9 mg tablet (swallow whole)",{"amount":38,"unit":27,"perUnit":22,"scored":28},9,[16],[41],{"source":32,"section":33},{"id":43,"form":22,"route":23,"label":44,"concentration":45,"markets":47,"refs":48},"tab-12","12 mg tablet (swallow whole)",{"amount":46,"unit":27,"perUnit":22,"scored":28},12,[16],[49],{"source":32,"section":33},[51,81],{"id":52,"disease":53,"label":54,"population":57,"type":61,"unit":27,"dose":62,"refs":67,"notes":70},"hd","huntington-chorea",{"fa":55,"en":56},"کره هانتینگتون — شروع ۶ mg دو بار در روز، هر هفته ۶ mg\u002Fروز بیشتر تا حداکثر ۴۸ mg","Huntington chorea — start 6 mg twice daily, +6 mg\u002Fday weekly up to 48 mg",{"minAge":58},{"value":59,"unit":60},18,"year","titration",{"dividedDoses":63,"titration":64},2,{"start":46,"increment":26,"incrementEveryDays":65,"max":66},7,48,[68],{"source":32,"section":69},"2.1",[71],{"text":72,"refs":75},{"fa":73,"en":74},"با غذا؛ دوز ۱۲ mg و بیشتر در دو نوبت. XR یک بار در روز. با مهارکننده قوی CYP2D6 یا متابولیزر ضعیف حداکثر ۳۶ mg. تعویض از تترابنازین طبق جدول ۲ برچسب.","With food; 12 mg\u002Fday or more in two doses. XR once daily. Strong CYP2D6 inhibitors or poor metabolizers: max 36 mg. Switching from tetrabenazine per label Table 2.",[76,77,79],{"source":32,"section":69},{"source":32,"section":78},"2.2",{"source":32,"section":80},"2.3",{"id":82,"disease":83,"label":84,"population":87,"type":61,"unit":27,"dose":89,"refs":91,"notes":93},"td","tardive-dyskinesia",{"fa":85,"en":86},"دیسکینزی دیررس — شروع ۶ mg دو بار در روز، هر هفته ۶ mg\u002Fروز بیشتر تا حداکثر ۴۸ mg","Tardive dyskinesia — start 6 mg twice daily, +6 mg\u002Fday weekly up to 48 mg",{"minAge":88},{"value":59,"unit":60},{"dividedDoses":63,"titration":90},{"start":46,"increment":26,"incrementEveryDays":65,"max":66},[92],{"source":32,"section":69},[94],{"text":95,"refs":96},{"fa":73,"en":74},[97,98,99],{"source":32,"section":69},{"source":32,"section":78},{"source":32,"section":80},[101],{"id":102,"severity":103,"text":104,"refs":107},"ci","block",{"fa":105,"en":106},"هانتینگتون با افکار خودکشی یا افسردگی درمان‌نشده؛ نارسایی کبد؛ رزرپین (۲۰ روز)؛ MAOI (۱۴ روز)؛ تترابنازین یا والبنازین.","Huntington’s with suicidality or untreated depression; hepatic impairment; reserpine (20 days); MAOIs (14 days); tetrabenazine or valbenazine.",[108],{"source":32,"section":109},"4",[111,118],{"text":112,"refs":115},{"fa":113,"en":114},"هشدار جعبه‌ای: افسردگی و افکار خودکشی در بیماری هانتینگتون؛ در افسردگی درمان‌نشده یا افکار خودکشی ممنوع.","Boxed warning: depression and suicidality in Huntington’s disease; contraindicated with untreated depression or suicidality.",[116],{"source":32,"section":117},"Boxed Warning",{"text":119,"refs":122},{"fa":120,"en":121},"طولانی شدن QT؛ سندرم نورولپتیک بدخیم؛ آکاتیزی و پارکینسونیسم؛ خواب‌آلودگی.","QT prolongation; neuroleptic malignant syndrome; akathisia and parkinsonism; sedation.",[123],{"source":32,"section":124},"5",[],[],[],{"status":129,"reviewer":130,"date":130},"unverified",null,[132,137],{"regimen":52,"formulation":21,"input":133,"expect":136},{"ageYears":134,"weightKg":135},45,70,{"perDose":26,"tabletsPerDoseRounded":5},{"regimen":82,"formulation":21,"input":138,"expect":141},{"ageYears":139,"weightKg":140},55,75,{"perDose":26,"tabletsPerDoseRounded":5},[143],"N07XX16",{"status":145,"refs":146},"not-found",[147],{"source":148,"section":149,"url":150},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Deutetrabenazine",{"kind":152,"refs":153,"id":156},"NDA",[154],{"source":32,"section":155},"SPL approval \u002F marketing category","NDA208082",[158,161,165,168],{"kind":159,"url":160,"label":156},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=208082",{"kind":162,"url":163,"label":164},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0","FDA Austedo",{"kind":166,"url":167,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa617022.html",{"kind":169,"url":170,"label":143},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N07XX16",{"pregnancy":172,"lactation":181,"pediatric":189,"geriatric":197},{"level":173,"text":174,"quote":177,"refs":178},"caution",{"fa":175,"en":176},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate data on the developmental risk associated with the use of AUSTEDO XR or AUSTEDO in pregnant women.",[179],{"source":32,"section":180},"8.1",{"level":173,"text":182,"quote":185,"refs":186},{"fa":183,"en":184},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of deutetrabenazine or its metabolites in human milk, the effects on the breastfed infant, or the effects of the drug on milk production.",[187],{"source":32,"section":188},"8.2",{"level":173,"text":190,"quote":193,"refs":194},{"fa":191,"en":192},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Chorea associated with Huntington’s Disease and Tardive Dyskinesia The safety and effectiveness of AUSTEDO XR and AUSTEDO have not been established in pediatric patients for the treatment of chorea associated with Huntington’s disease or for the treatment of tardive dyskinesia.",[195],{"source":32,"section":196},"8.4",{"level":173,"text":198,"quote":201,"refs":202},{"fa":199,"en":200},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of hepatic, renal, and cardiac dysfunction, and of concomitant disease or other drug therapy.",[203],{"source":32,"section":204},"8.5",1792156173396]